0 761

Cited 13 times in

The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

DC Field Value Language
dc.contributor.author김수정-
dc.contributor.author김유리-
dc.contributor.author김진석-
dc.contributor.author민유홍-
dc.contributor.author양우익-
dc.contributor.author정준원-
dc.date.accessioned2017-10-26T07:11:37Z-
dc.date.available2017-10-26T07:11:37Z-
dc.date.issued2016-
dc.identifier.issn0939-5555-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/151721-
dc.description.abstractThe non-germinal center B cell (non-GCB) subtype of diffuse large B cell lymphoma (DLBCL) is more related to poor prognosis than the GCB subtype. To investigate the role of molecular classification according to upfront autologous hematopoietic stem cell transplantation (ASCT), we retrospectively evaluated 219 newly diagnosed high-risk DLBCL patients. Eighty-one patients were in the ASCT group, and 138 patients were in the non-ASCT group. The ASCT group yielded significantly better overall survival (OS) and progression-free survival (PFS) than the non-ASCT group (p = 0.038 and p = 0.007), and patients with the non-GCB subtype were more related to inferior PFS than those with the GCB subtype (p = 0.020). After performing age-matching by using propensity scores, upfront ASCT continued to show better OS and PFS than non-ASCT (p = 0.046 and p = 0.026). In the non-ASCT group, the non-GCB subtype showed worse OS and PFS than the GCB subtype (p = 0.039 and p = 0.007). Patients who achieved complete response showed differences in OS and PFS according to molecular subtype (p = 0.007 and p = 0.002). In the ASCT group, there were no significant differences in OS and PFS according to molecular classification (p = 0.277 and p = 0.892). In conclusion, non-GCB subtype DLBCL patients showed poor OS and PFS in the non-ASCT group while they did not show clinical significance in the ASCT group. This suggests the possibility that upfront ASCT may improve the poor prognosis of non-GCB subtype in high-risk DLBCL.-
dc.description.statementOfResponsibilityrestriction-
dc.publisherSpringer International-
dc.relation.isPartOfANNALS OF HEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHFemale-
dc.subject.MESHHematopoietic Stem Cell Transplantation/methods*-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHL-Lactate Dehydrogenase/blood-
dc.subject.MESHL-Lactate Dehydrogenase/metabolism*-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/blood-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/classification-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOutcome Assessment (Health Care)/methods-
dc.subject.MESHOutcome Assessment (Health Care)/statistics & numerical data-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRemission Induction-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTransplantation, Autologous-
dc.subject.MESHYoung Adult-
dc.titleThe different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase-
dc.typeArticle-
dc.publisher.locationGermany-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYu Ri Kim-
dc.contributor.googleauthorSoo-Jeong Kim-
dc.contributor.googleauthorJune-Won Cheong-
dc.contributor.googleauthorDeok-Hwan Yang-
dc.contributor.googleauthorHyewon Lee-
dc.contributor.googleauthorHyeon-Seok Eom-
dc.contributor.googleauthorYong Oh Sung-
dc.contributor.googleauthorHyo Jung Kim-
dc.contributor.googleauthorHye Jin Kang-
dc.contributor.googleauthorWon-Sik Lee-
dc.contributor.googleauthorYong Park-
dc.contributor.googleauthorWoo-Ick Yang-
dc.contributor.googleauthorYoo Hong Min-
dc.contributor.googleauthorJin Seok Kim-
dc.identifier.doi10.1007/s00277-016-2729-4-
dc.contributor.localIdA00779-
dc.contributor.localIdA01017-
dc.contributor.localIdA01407-
dc.contributor.localIdA02300-
dc.contributor.localIdA03729-
dc.contributor.localIdA00633-
dc.relation.journalcodeJ00161-
dc.identifier.eissn1432-0584-
dc.identifier.pmid27324387-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00277-016-2729-4-
dc.subject.keywordAutologous hematopoietic stem cell transplantation-
dc.subject.keywordDiffuse large B cell lymphoma-
dc.subject.keywordGerminal center B cell-
dc.subject.keywordNon-germinal center B cell-
dc.subject.keywordRituximab-
dc.contributor.alternativeNameKim, Soo Jeong-
dc.contributor.alternativeNameKim, Yu Ri-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNameYang, Woo Ick-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.affiliatedAuthorKim, Yu Ri-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorYang, Woo Ick-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.contributor.affiliatedAuthorKim, Soo Jeong-
dc.citation.volume95-
dc.citation.number9-
dc.citation.startPage1491-
dc.citation.endPage1501-
dc.identifier.bibliographicCitationANNALS OF HEMATOLOGY, Vol.95(9) : 1491-1501, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid45734-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.